Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some statements are supported by the provided label excerpts (notably that grapefruit juice can increase atorvastatin plasma concentrations via CYP3A4 inhibition; and that excessive grapefruit juice (>1.2 L/day) increases plasma concentrations). However, multiple claims about orange juice timing, 'no universal time gap,' and guidance based on 'avoid citrus juice specifically' are not supported or are framed more broadly than the label excerpt provides.
Category Scores
Accurate Statements
Grapefruit (and grapefruit-derived products) can increase atorvastatin levels in the blood.
Supported by Section 7.2 (Grapefruit Juice): grapefruit juice contains components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin.
Grapefruit compounds can affect the metabolism of atorvastatin.
Supported by Section 7.2 description that grapefruit juice components inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin (i.e., via CYP3A4 effects).
Increased atorvastatin blood levels can raise the risk of side effects.
Partially supported: label excerpt for grapefruit juice states increased plasma concentrations can occur (Section 7.2), but it does not explicitly state risk of side effects. Therefore, this is not fully supported (see unsupported/omissions).
Unsupported Statements
There is no single universal recommended time gap between taking Lipitor (atorvastatin) and orange juice.
No label excerpt provided specifies any timing interval for orange juice or states that no universal time gap exists.
The issue with juices and atorvastatin is the amount of certain juices (especially grapefruit and grapefruit-derived products) that can interact with statins.
Label excerpt addresses grapefruit juice interaction via CYP3A4 inhibition and notes increased plasma concentrations especially with excessive grapefruit juice consumption (>1.2 liters/day). It does not state this as the only/primary issue for juices broadly.
Orange juice is not considered a grapefruit-type juice.
No label excerpt defines orange juice or classifies it relative to grapefruit-type juice.
For most people, no set number of hours is generally required to separate Lipitor from orange juice.
No label excerpt provides dosing/administration timing guidance related to orange juice.
Orange juice typically does not have the same effect as grapefruit.
No label excerpt compares orange juice to grapefruit juice.
If someone has been told to avoid 'citrus juice' specifically, they should follow the exact instructions received.
No label excerpt contains instructions about 'citrus juice' avoidance or how patients should interpret clinician-provided wording beyond the stated grapefruit juice interaction.
Grapefruit and grapefruit juice should be avoided altogether while taking atorvastatin unless the clinician specifically says otherwise.
Label excerpt does not state an absolute requirement to avoid grapefruit entirely; it states grapefruit juice can increase plasma concentrations, especially with excessive consumption (>1.2 liters/day).
Timing does not fully solve the interaction with grapefruit because grapefruit compounds can affect the metabolism of the drug.
Label excerpt does not discuss timing as a mitigation strategy or explicitly describe metabolism beyond CYP3A4 inhibition effects.
Accidentally having orange juice right around the Lipitor dose usually is not a problem.
No label excerpt provides safety guidance for orange juice or accidental ingestion near dosing.
If grapefruit juice was taken, contacting a pharmacist or prescriber for specific guidance is recommended.
No label excerpt provides guidance to contact a pharmacist/prescriber after grapefruit juice intake.
If grapefruit juice was taken and unusual muscle pain, weakness, or dark urine occurs, specific guidance should be sought.
Label excerpt includes skeletal muscle warning content (e.g., myopathy/rhabdomyolysis and withholding/discontinuing in patients with acute, serious conditions suggestive of myopathy), but it does not provide an explicit instruction framed as 'if grapefruit juice was taken and symptoms X occur, seek guidance.'
Contradictions
Important Omissions
Grapefruit juice interaction is specifically described in the label as being especially associated with excessive grapefruit juice consumption (>1.2 liters/day). The AI response did not include this threshold.
Importance:
Moderate
The AI response did not convey that the label interaction is tied to grapefruit juice components inhibiting CYP3A4 and increasing plasma concentrations (and that the label excerpt does not define orange juice equivalence).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements extend beyond the provided labeling excerpt (e.g., suggesting avoidance of grapefruit altogether unless clinician says otherwise, asserting lack of any timing effect/interval for orange juice, and advising contact for grapefruit after ingestion). While the core grapefruit interaction is supported, the broader practical guidance may mislead relative to what the excerpt specifies (including the >1.2 L/day emphasis).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Overgeneralization beyond the excerpt regarding orange juice timing, absolute grapefruit avoidance, and symptom/contact guidance not explicitly stated in the provided label text.
Suggested Improvement
Limit claims to what the label excerpt states for grapefruit juice (CYP3A4 inhibition and increased atorvastatin plasma concentrations, especially with excessive intake >1.2 L/day). Remove or rephrase unsupported assertions about orange juice and any universal timing guidance; avoid stating 'avoid altogether' unless supported by the label excerpt provided.